Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
palmitoleic acid + infliximab
- Development stage
- Unknown
- Lead developer
- Chinese Medical Association
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of palmitoleic acid, a mono-unsaturated fatty acid, and infliximab, a chimeric monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α). This combination is being investigated by the Chinese Medical Association for the treatment of active Crohn's disease, specifically to promote intestinal mucosal healing. Palmitoleic acid acts as a small molecule anti-inflammatory agent that may reprogram gut microbiota and enhance the therapeutic response to anti-TNF-α biologics. Infliximab is an established biologic that neutralizes the biological activity of TNF-α by binding with high affinity to the soluble and transmembrane forms of the cytokine.
- Other names
- palmitoleic acid combined with infliximab
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on palmitoleic acid + infliximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on palmitoleic acid + infliximab.